Pimobendan , ≥99% , 74150-27-9

Synonym(s):
(RS)-6-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone;Pimobendan

CAS NO.：74150-27-9

Empirical Formula: C19H18N4O2

Molecular Weight: 334.37

MDL number: MFCD00761648

EINECS: 640-420-7

PRODUCT Properties

• Melting point: approximate 243℃ (dec.)
• Density: 1.36
• storage temp.: 2-8°C
• solubility: DMSO: soluble5mg/mL, clear (warmed)
• form: powder
• pka: 10.55±0.10(Predicted)
• color: white to beige
• InChI: InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
• InChIKey: GLBJJMFZWDBELO-UHFFFAOYSA-N
• SMILES: C1(=O)NN=C(C2C=C3NC(C4=CC=C(OC)C=C4)=NC3=CC=2)C(C)C1

Description and Uses

Pimobendan, a novel cardiotonic vasodilator, was introduced in Japan for the treatment of acute and mild to moderate chronic heart failure. It is a phosphodiesterase Ⅲ inhibitor and is able to enhance sensitization of myocardial contractile regulatory protein to calcium ions. The combination of these effects contribute to its inotropic activity. In patients with severe congestive heart failure, orally administered pimobendan improves cardiac index, stroke volume index, pulmonary wedge pressure, and systemic and pulmonary vascular resistance. Pimobendan is reported to be well tolerated and largely devoid of the proarrhythmic effects of classical phosphodiesterase Ill inhibitors. Studies also suggested that combination of the inotropic agent pimobendan with an ACE inhibitor such as enalapril may be superior to monotherapy for heart failure patients.

Pimobendan is a cardiotonic agent. The study of the cardiotonic mechanism of Pimobendan using ventricular muscles from rabbits and guinea pigs suggests that Pimobendan acts by inhibiting phosphodiesterase III and potassium channel. The potent venodilating action of Pimobendan makes it a suitable treatment option for patients with congestive heart failure (CHF) as it also improves systemic vasoconstriction.

Safety

• Symbol(GHS): GHS06
• Signal word: Danger
• Hazard statements: H301
• Precautionary statements: P301+P310+P330
• RIDADR: UN 2811 6.1 / PGIII
• HS Code: 2933995300